8-K – 2025-12-22 – d45090d8k.htm

Fulltext

8-K

BIOMARIN PHARMACEUTICAL INC false 0001048477 0001048477 2025-12-19 2025-12-19
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 

FORM 8-K
 
 

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 19, 2025
 
 

BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)
 
 

 

Delaware
 
000-26727
 
68-0397820

(State or other jurisdiction
of incorporation or organization)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
 

770 Lindaro Street
 
San Rafael
 
California
 
94901

(Address of Principal Executive Offices)
 

 

 
(Zip Code)
(415) 506-6700
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
 
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
 

Title of each class

 
Trading
Symbol(s)

 
Name of each exchange
on which registered

Common Stock, par value $0.001
 
BMRN
 
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 

Item 8.01
Other Events.

On December 19, 2025, BioMarin Pharmaceutical Inc. announced its decision to discontinue development of BMN 349, an oral therapeutic for Alpha-1 antitrypsin deficiency (AATD)-associated liver disease.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 

 

 

 
BioMarin Pharmaceutical Inc.,
a Delaware corporation

Date: December 22, 2025
 

 
By:
 
/s/ G. Eric Davis

 

 

 
G. Eric Davis

 

 

 
Executive Vice President, Chief Legal Officer